The American Chemical Society (ACS) is seeking nominations for C&EN’s 10 Start-ups to Watch
Date posted 3 March 2021 Deadline 1 August 2021 ACS is looking for companies that are using chemistry to solve the world’s most pressing problems. Firms that have made our list are developing pharmaceuticals, materials, green chemistry processes,…
Monash University and PureTech Health develop novel technology platform that targets drugs to the lymphatics and lymph nodes
Date posted – 26 February 2021 Researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) and PureTech Health (LSE: PRTC, Nasdaq: PRTC) have developed a novel technology platform that directly targets gut lymphatics and has great potential to…
Medical devices reforms: Personalised medical devices
25 February 2021 Please note: While submission of a notification to the TGA is required within two (2) months of initial manufacture/supply of a custom-made medical device, many stakeholders have not been meeting this obligation. If you were supplying…
VivaZome and La Trobe University enter new research collaboration to develop exosome therapeutics.
16 February 2021 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University today announced that they have entered into a new collaborative research project focussed on developing novel exosome therapeutics. Under the collaborative arrangement, VivaZome scientists will work…
TGA approves first Australian commercial CAR-T manufacturing site – bringing faster access to eligible Australians with life-threatening blood cancers
12 February 2021 • Kymriah® (tisagenlecleucel)[pronounced kim-RY-uh], a chimeric antigen receptor T cell (CAR-T) one-time treatment, will be the first commercially approved CAR-T therapy to be manufactured in Australia • Providing manufacturing capabilities in Australia will help reduce…
New appointments at Biointelect
12 February 2021 Biointelect has made several new appointments to its Sydney and Melbourne-based teams as it experiences strong growth across all its three main consulting workstreams: R&D strategy and planning, biotech commercialisation and strategic market access, health…
First-hand experience sparks Rhinomed to develop high comfort swab
Posted 10 December 2020 This is a BioMelbourne Network Good News Story – click here to find out more and submit yours. In April this year, as the world came to grips with the global COVID-19 pandemic, Rhinomed CEO Michael…
Monash University partners with HuiKang Bio-Tech to develop new class of anti-infectives
7 December 2020 Monash University has announced a collaboration with leading protein and peptide experts, HuiKang Bio-Tech, to develop a new class of anti-infectives. The collaboration is being led by Professor Ray Norton from the Monash Institute of…
Stephens Lawyers & Consultants: ACCC Enforcement Proceedings – Unfair Contract Terms
1 December 2020 From Katarina Klaric (Principal & Director) and Peter Divitcos (Lawyer), Stephens Lawyers & Consultants Standard form contracts are being subjected to increased scrutiny for unfair contract terms by regulators. On-line terms and conditions are of…
mexec uses COVID grant to assist industry job seekers
Posted 26 November 2020 This is a BioMelbourne Network Good News Story – click here to find out more and submit yours. With companies across the industry forced to let staff go, Marilyn Jones knew that 2020 was…
Kynetyka’s DVTect™ technology granted Australian patent.
Posted 25 November 2020 Melbourne Australia: Kynetyka Technologies Pty Ltd (“Kynetyka”), a privately held Melbourne-based medical device company is pleased to announce that the Australian patent for its DVTect™ technology has been granted. The patent “A screening test…
Even from a distance, Commercial Eyes is thriving
Posted 12 November 2020 This is a BioMelbourne Network Good News Story – click here to find out more and submit yours. This story was submitted by Andrew Carter, Managing Director Do you remember saying – “I catch…
